Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate whether the HIV vaccine ALVAC vCP1452 given in combination with
interleukin-2 (IL-2), also known as aldesleukin, can increase immune system function in
people with HIV infection.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)